Although adherence to labor laws is a crucial aspect of managing any facility, this story has additional lessons to be learned and shared. Supply chain management and security have been hot topics of conversation among the pharmaceutical industry for the past several years. The increase of counterfeiting, economically motivated adulteration, and globalization throughout the pharma industry—much like that of the electronics or any other major industry—only adds to supply chain complexity.
And here is where due diligence comes into play. First, companies must visit their global sites. According to the Times article mentioned above, two Apple employees pointed out that Jobs never visited the company's factories in China. It seems that Cook, in his new role, is aiming to change that practice by taking a first-hand look inside the facilities that are manufacturing Apple's products. And because he, like most chief executives, cannot spend every day visiting and auditing sites, he's asking a third party to help (i.e., FLA). The pharma industry has similar options through third-party auditing organizations and consortiums. No matter the time or cost, knowing what's going on inside your facilities is always going to be worth the effort.Second, companies must keep their communication lines open. In one section of the FLA report about Foxconn, the association notes specifically that "communication is a two-way process.... The more workers participate in those processes, the more they are accepted, trusted and effective" (1). Some of Foxconn's problems are reportedly tied to top-down only communication. How many times have you heard someone in industry say that the Quality team doesn't communicate with the Development team, or that Senior Management doesn't communicate with the Technicians, and so on. Listening to employees—no matter their department or division—can only lead to improvement at all levels.
Third, companies need to be transparent. Cook seems to be taking this seriously. A January 2012 Apple report included for the first time the names of companies that supply Apple with parts and services, something it had previously declined to do (3). Apple's site also notes that it's audited every "final assembly factory in its supply chain each year since 2006" (4). The key phrase here is "final assembly." We know from recent unfortunate events, that the final manufacturer, distributor, or assembler is not necessarily where problems can occur. Quality must be sewn into and confirmed throughout every point in a product's supply chain. Regulators have enforced this message repeatedly.
I believe these points are must-do's to help secure the industry's product supply chain. A statement by Apple to the Times, noted that, "Our team has been working for years to ... make Apple's supply chain a model for the industry.." (5). Clearly, the company still has some work to do—and so does pharma. But I think we're all headed in the right direction.
Sources: 1. FLA, Foxconn Invest. Report, Mar. 29, 2012. 2. D. Barboza, N.Y. Times online, June 6, 2010. 3. N. Wingfield, N.Y. Times online, Apr. 1, 2012. 4. Apple Press Release, Feb. 13, 2012. 5. C. Duhigg, S. Greenhouse, N.Y. Times online, Mar. 29, 2012.
Angie Drakulich is the editorial director of BioPharm International.